Regeneron's Bold Vision: Charting the Future of Healthcare at Bernstein Insights

When Regeneron Pharmaceuticals stepped up to the podium at the 3rd Annual Bernstein Insights: Healthcare Leaders and Disruptors Forum in September 2026, it wasn't just another corporate presentation. It was a chance for Ryan Crowe, their Senior VP of Investor Relations, and Christopher Fenimore, the Executive VP of Finance & CFO, to paint a vivid picture of a company truly pushing the boundaries of medical science. They sat down with Bernstein's own Jeffrey Walch, offering a candid look at where Regeneron stands and where it's headed. You could feel the excitement, tinged with a healthy dose of strategic realism, in their updates.

Let's talk about some of the big wins. EYLEA HD, for instance, has truly seen its moment in the spotlight. Just last quarter, in Q4 2025, it secured some fantastic label enhancements. Imagine, patients now potentially benefiting from every 4-week dosing, plus an expanded indication for RVO. That's a significant leap for vision care, offering both convenience and broader applicability.

And then there’s Libtayo, a testament to Regeneron's growing prowess in oncology. It posted an impressive over 30% year-over-year growth last quarter, which, in the competitive cancer therapy landscape, is truly something to celebrate. The addition of adjuvant CSCC to its label about a year ago certainly bolstered its position, demonstrating its versatility in fighting skin cancers.

Of course, no discussion of the pharmaceutical market would be complete without acknowledging the looming patent cliff. The elephant in the room for many, KEYTRUDA (Pembrolizumab), is facing its own Loss of Exclusivity (LOE) eventually. The precise timing and the full market impact are still a bit of a moving target, keeping everyone on their toes.

Then we turn to Dupixent (dupilumab), arguably one of Regeneron's most successful ventures. While a phenomenal drug, its composition of matter patents are set to expire, first in the U.S. in March 2031, followed by Europe in 2033, and Japan in 2034. Dosing patents for asthma and atopic dermatitis will hold on a bit longer, into the mid-2030s. The big question, naturally, is when biosimilar versions might finally hit the market. For now, it's still anyone's guess, adding an element of uncertainty to its long-term revenue projections.

But it’s not all about existing blockbusters. Regeneron's pipeline is bustling with promising new therapies. The C5 Franchise, featuring cemdisiran and pozelimab, is one to watch. Cemdisiran, an siRNA therapy for generalized myasthenia gravis, has a PDUFA date scheduled for November 2026 – a truly pivotal moment. We're also anticipating registration-enabling data for a PNH study in Q4 2026, along with an interim analysis for a geographic atrophy study around the same time. However, it's worth noting the potential for infection risk with C5 inhibition in elderly geographic atrophy patients, a careful balance they’ll need to manage. Plus, the PNH study's co-primary endpoint of transfusion avoidance could be tricky, as not all transfusions are directly tied to intravascular hemolysis.

In oncology, Linvoseltamab (Lynozyfic) recently gained approval for late-line multiple myeloma, offering new hope for patients with limited options. Odronextamab is also making strides, with ongoing studies in follicular lymphoma and DLBCL, suggesting a potential U.S. approval might be just around the corner. The PD-1, LAG-3 program, combining fianlimab with Libtayo, presented first-line metastatic melanoma data earlier in 2026. While it showed over five months of benefit, it didn't quite hit statistical significance. Nevertheless, the adjuvant melanoma trial data expected late 2026 or early 2027 is still eagerly awaited, though approached with caution given Opdualag's previous challenges in this setting.

Beyond oncology, Regeneron is exploring diverse therapeutic areas. Their Factor XI Program, involving two distinct antibodies, is expected to yield initial Phase III data in VTE prevention studies in 2027. And for atrial fibrillation, short-duration Phase II data is anticipated by mid-2027. They're also making headway with an NPR1 Antibody for Postural Orthostatic Tachycardia Syndrome (POTS), a debilitating condition. Phase II data is slated for presentation later in 2026, and active discussions with the FDA about the regulatory path are ongoing – a sign of their commitment to addressing unmet needs.

The siRNA portfolio, a significant collaboration with Alnylam, continues to be a fertile ground for innovation. Regeneron holds global rights for cemdisiran. In liver targets, especially for MASH (like HSD17B13, CIDEB, and PNPLA3 mutants), data for HSD17B13 and CIDEB are expected later in 2026, with CIDEB notably presenting its very first clinical data. While Alnylam is advancing ALN-APP for Alzheimer's (Regeneron opted out but retains royalties), Regeneron is still very much involved in other neuroscience programs, with ALS (SOD1 mutants) having begun dosing patients in 2024 and data likely in 2027. Programs for Huntington’s and Parkinson’s are also making their way through the clinic.

Finally, a quick nod to some truly impactful rare disease initiatives: DB-OTO, approved for genetic hearing loss, is being provided to patients for free in a commendable partnership with the U.S. government. And Garetosmab is making a difference for those living with Fibrodysplasia Ossificans Progressiva (FOP). It’s clear that under the guidance of leaders like George Yancopoulos, driving the scientific engine, and Len, embodying the "do well by doing good" philosophy, Regeneron continues to innovate across a remarkably broad spectrum, balancing commercial success with a genuine commitment to patients.